NCT06458504 Viral Infection of HSPC Impacts Hematopoiesis
| NCT ID | NCT06458504 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | HIV-1 |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-10-25 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2024-10-25 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Eligibility Criteria
Inclusion Criteria: HIV patients : * HIV-positive patients with a negative or positive viral load. * managed at Ambroise Paré Hospital. * patients with a bone marrow biopsy or myelogram performed as part of their care. Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology. Management at Ambroise Paré Hospital. Exclusion Criteria: \-
Contact & Investigator
Claude CAPRON, MD, PhD
PRINCIPAL INVESTIGATOR
Laboratory of Immunology, Ambroise Paré hospital - APHP
Frequently Asked Questions
Who can join the NCT06458504 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV-1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06458504 currently recruiting?
Yes, NCT06458504 is actively recruiting participants. Contact the research team at claude.capron@aphp.fr for enrollment information.
Where is the NCT06458504 trial being conducted?
This trial is being conducted at Boulogne-Billancourt, France.
Who is sponsoring the NCT06458504 clinical trial?
NCT06458504 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Claude CAPRON, MD, PhD at Laboratory of Immunology, Ambroise Paré hospital - APHP. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.